Spring Bank Pharmaceuticals (NASDAQ: SBPH) is one of 306 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Spring Bank Pharmaceuticals to related companies based on the strength of its analyst recommendations, valuation, earnings, profitability, institutional ownership, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Spring Bank Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spring Bank Pharmaceuticals 0 1 4 0 2.80
Spring Bank Pharmaceuticals Competitors 785 3121 11399 227 2.71

Spring Bank Pharmaceuticals currently has a consensus price target of $27.25, indicating a potential upside of 52.15%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.34%. Given Spring Bank Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Spring Bank Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Spring Bank Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spring Bank Pharmaceuticals N/A -74.73% -47.49%
Spring Bank Pharmaceuticals Competitors -5,351.34% -488.28% -42.81%

Valuation & Earnings

This table compares Spring Bank Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Spring Bank Pharmaceuticals $350,000.00 -$17.36 million -6.51
Spring Bank Pharmaceuticals Competitors $290.00 million $35.57 million 150.23

Spring Bank Pharmaceuticals’ competitors have higher revenue and earnings than Spring Bank Pharmaceuticals. Spring Bank Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

28.0% of Spring Bank Pharmaceuticals shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.6% of Spring Bank Pharmaceuticals shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Spring Bank Pharmaceuticals has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Spring Bank Pharmaceuticals’ competitors have a beta of 2.71, indicating that their average stock price is 171% more volatile than the S&P 500.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).

Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.